The company continues to remain positive in its goal of becoming cash flow positive by the end of 2025." Chief executive Anders Lundstrom added: "We are entering Q2 with clear momentum behind ACCRUFeR ...

Recce will have a strong pro-forma cash position post Capital Raising of A$17.7 million. In addition, the Company expects: additional estimated R&D rebate of A$8.5 million from the ATO (expected Q4 ...

The joint proxy statement/prospectus are being mailed to all Alumis ... with committed capital for a clinical development plan to evaluate its potential differentiation Pro forma cash of approximately ...

The joint proxy statement/prospectus are being mailed ... development plan to evaluate its potential differentiation Pro forma cash of approximately $737 million as of December 31, 2024, provides ...